Previous 10 | Next 10 |
-- Sabizabulin for COVID-19 Emergency Use Authorization Application Submitted to U.S. FDA in June 2022-- --The UK’s Medicines and Healthcare Products Regulatory Agency Informed the Company that its Sabizabulin Marketing Authorization Application Will Receive Exp...
Since the mid-June lows, highly shorted names have again been outperforming. On a relative basis, the most heavily shorted stocks have been outperforming the Russell 3,000 in that time. This has resulted in the relative strength line to break out of the downtrend that has been in ...
Veru ( NASDAQ: VERU ) is scheduled to announce Q3 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.15 (-400.0% Y/Y) and the consensus Revenue Estimate is $17.08M (-3.3% Y/Y). Over the last 1 year, VERU has beaten EPS es...
MIAMI, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Phase 3 COVID-19 study ...
The biotech industry for the first half of the year had seen better six-month periods in the past, but the situation appears to have changed beginning in July. From Jan. 1 to June 20, 2022, the SPDR S&P Biotech ETF ( XBI ) and iShares Nasdaq Biotechnology ETF ( IBB ) had...
Oppenheimer said that a new analysis conducted by Veru ( NASDAQ: VERU ) on mortality rates in a phase 3 trial of its COVID-19 therapy sabizabulin assuages concerns and will lead to an Emergency Use Authorization from the U.S. FDA. The firm cited a new corporate pres...
MIAMI, July 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that it will report financial re...
MIAMI, July 27, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the European Medicines Agen...
Clinical-stage biotech Veru ( NASDAQ: VERU ) announced on Monday that U.K. regulators agreed that the currently available safety and efficacy data for its experimental COVID-19 therapy sabizabulin would support an expedited review for a marketing application. The U.K. ...
MIAMI, July 25, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the United Kingdom’s...
News, Short Squeeze, Breakout and More Instantly...
MIAMI, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced th...
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced th...